Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Status:
Terminated
Trial end date:
2015-03-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bortezomib works in treating patients with high-risk
acute myeloid leukemia (AML) in remission. Bortezomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth